Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
26 March 2025
| Name: | AVANTOGEN LIMITED (ACU) (This company subsequently changed its name and is now PLUS CONNECT LIMITED. You should refer to that name for Status.) | ||||||||||||
| Date of Listing: | 25 August 1971 | ||||||||||||
| Subsequent Names: |
| ||||||||||||
| Former Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now PLUS CONNECT LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now PLUS CONNECT LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now PLUS CONNECT LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| PLUS CONNECT LIMITED | 09/05/2018 | |
| ACTIVISTIC LIMITED | 13/05/2015 | 09/05/2018 |
| ACUVAX LIMITED | 05/12/2008 | 13/05/2015 |
| AVANTOGEN LIMITED | 31/05/2005 | 05/12/2008 |
| AUSTRALIAN CANCER TECHNOLOGY LIMITED | 04/05/2001 | 31/05/2005 |
| EXODUS MINERALS LIMITED | 14/08/1997 | 04/05/2001 |
| MINERALS MINING AND METALLURGY LIMITED | 14/08/1997 |
REGISTRY:
Security Transfer Australia Pty Ltd
No longer operating
name changed to Acuvax Limited | 05/12/2008 |
securities reinstated to quotation | 03/10/2007 |
releases its 2007 annual report | 27/09/2007 |
releases progress report - expects to hold an annual general meeting about 30 November 2007 | 19/09/2007 |
the company is going to apply to ASX for the re-quotation of its shares | 06/09/2007 |
company releases its Preliminary Final Report | 31/08/2007 |
company releases its Half Yearly Report and Accounts | 07/08/2007 |
at the AGM on 11 June, all resolutions were passed on a show of hands | 13/06/2007 |
the company issues another 274m shares and now has 548m on isuue | 22/05/2007 |
releases supplementary prospectus & advises of completion of rights issue | 16/05/2007 |
provides Notice of AGM for 4pm on 11 June at office of Lavan Legal , Level 20, 1 William St, Perth | 11/05/2007 |
the company completes major transaction with SciClone Pharmaceuticals Inc | 27/04/2007 |
company releases its Annual Report | 24/04/2007 |
the company announces that it has entered into a strategic alliance with The Medingen Group, LLC of Canandaigua, New York to sublicense a line of nutraceutical products previously known as `revisys', which will subsequently be re-branded under the name `Encore' | 15/03/2007 |
releases a Half Yearly Report | 01/03/2007 |
releases its unaudited 2006 Financial Statements | 28/02/2007 |
ASIC issues an interim stop order on the rights issue prospectus | 28/02/2007 |
cash flow for the quarter ended 30 December 2006 reflects a deficit at operating level of $1,847k | 30/01/2007 |
releases top 20 shareholders/Distribution Schedule | 10/01/2007 |
the company releases a copy of a Form 8-K that has been filed by Avantogen Oncology Inc with the SEC in the US - Avantogen Limited has a 54% interest in Avantogen Oncology Inc - in their release to the ASX, the directors should have explained the implications of this filing for shareholders | 20/12/2006 |
shareholders are reminded that the Chopin offer closes at 12 midnight tomorrow (Wednesday) evening - the offer is not fair as the total consideration is less than the market value of the assets to be acquired - but in consideration of other factors, the offers are reasonable | 19/12/2006 |
Chopin grants shareholders an extension of time to approve loan facilities | 19/12/2006 |
company provides quite a detailed update - the cash position is deteriorating and efforts are being made to re-finance the company - shareholders should read the update which can be sourced at www.asx.com.au | 14/12/2006 |
directors attempt to report on what transpired at the AGM on November 30 is abysmal - one shareholder asked questions about the takeover and at the very least directors should have reported to all shareholders on the substance of the questions and answers | 01/12/2006 |
directors advise of a deteriorating cash position and of attempts to seek further funding | 30/11/2006 |
the meeting to be held at 4:30pm on 30 November at McCullough Robertson, Level 11, Central Plaza Two, 66 Eagle Street, Brisbane is to proceed but it will no longer be an AGM as the company has not finalised the financial statements - it will be a special meeting allowing shareholders to put questions to the board | 24/11/2006 |
company files its quarterly report | 14/11/2006 |
advises in relation to the Chopin Opus bid, that the defeating conditions of the Bidder's Statement (s 3.7) have been waived | 10/11/2006 |
AGM to be held at 4:30pm on 30 November at McCullough Robertson, Level 11, Central Plaza Two, 66 Eagle Street, Brisbane | 08/11/2006 |
ASIC has refused the company's application for an extension of time to hold its AGM and the company will now make arrangements to hold it as soon as practicable | 03/11/2006 |
company secures a $200,000 loan facility for its immediate short term financing needs | 31/10/2006 |
cash flow report for the quarter to 30 September 2006 reflects a deficit at operating level of $1851k for the quarter | 30/10/2006 |
ASX queries the company regarding Listing Rule 10.1 and the company states that it applies to the loan agreement between Anvantogen Oncology and Chopin Opus (see note immediately below) and accordingly the company will seek shareholder approval "for grant of the security by way of promissory note and the issue of the warrants prior to the warrants being issued" | 27/10/2006 |
the company releases a copy of a Form 8-K that has been filed by Avantogen Oncology Inc with the SEC in the US - Avantogen Limited has a 54% interest in Avantogen Oncology Inc - in their release to the ASX, the directors should have explained the implications of this filing for shareholders | 19/10/2006 |
advises of minor amendments to the bidder's statement | 17/10/2006 |
company reports it has sufficient cash to fund activities through to the end of November and is currently seeking additional funding of $200,000 | 17/10/2006 |
releases Bidder's Statement & Target's Statement re the Chopin Opus offer | 05/10/2006 |
Avantogen Ocology Inc submits an investigational drug application to the FDA for a compound being investigated for treatment of pancreatic cancer | 02/10/2006 |
company says it is doing everything possible to resolve the accounting issues underlying its suspension | 27/09/2006 |
Dr William Ardrey appointed CEO and Company Secretary | 25/09/2006 |
advises it has secured a $1.8 million Loan facility | 19/09/2006 |
lodges bidders statement from Chopin Opus | 19/09/2006 |
lodges initial response to bidders statement from Chopin Opus | 19/09/2006 |
releases Preliminary Final Report | 14/09/2006 |
shares suspended from quotation pending resolution of accounting issues | 11/09/2006 |
name changed from Australian Cancer Technology Limited | 31/05/2005 |
name changed to Acuvax Limited | 05/12/2008 |
securities reinstated to quotation | 03/10/2007 |
releases its 2007 annual report | 27/09/2007 |
releases progress report - expects to hold an annual general meeting about 30 November 2007 | 19/09/2007 |
the company is going to apply to ASX for the re-quotation of its shares | 06/09/2007 |
company releases its Preliminary Final Report | 31/08/2007 |
company releases its Half Yearly Report and Accounts | 07/08/2007 |
at the AGM on 11 June, all resolutions were passed on a show of hands | 13/06/2007 |
the company issues another 274m shares and now has 548m on isuue | 22/05/2007 |
releases supplementary prospectus & advises of completion of rights issue | 16/05/2007 |
provides Notice of AGM for 4pm on 11 June at office of Lavan Legal , Level 20, 1 William St, Perth | 11/05/2007 |
the company completes major transaction with SciClone Pharmaceuticals Inc | 27/04/2007 |
company releases its Annual Report | 24/04/2007 |
the company announces that it has entered into a strategic alliance with The Medingen Group, LLC of Canandaigua, New York to sublicense a line of nutraceutical products previously known as `revisys', which will subsequently be re-branded under the name `Encore' | 15/03/2007 |
releases a Half Yearly Report | 01/03/2007 |
releases its unaudited 2006 Financial Statements | 28/02/2007 |
ASIC issues an interim stop order on the rights issue prospectus | 28/02/2007 |
cash flow for the quarter ended 30 December 2006 reflects a deficit at operating level of $1,847k | 30/01/2007 |
releases top 20 shareholders/Distribution Schedule | 10/01/2007 |
the company releases a copy of a Form 8-K that has been filed by Avantogen Oncology Inc with the SEC in the US - Avantogen Limited has a 54% interest in Avantogen Oncology Inc - in their release to the ASX, the directors should have explained the implications of this filing for shareholders | 20/12/2006 |
shareholders are reminded that the Chopin offer closes at 12 midnight tomorrow (Wednesday) evening - the offer is not fair as the total consideration is less than the market value of the assets to be acquired - but in consideration of other factors, the offers are reasonable | 19/12/2006 |
Chopin grants shareholders an extension of time to approve loan facilities | 19/12/2006 |
company provides quite a detailed update - the cash position is deteriorating and efforts are being made to re-finance the company - shareholders should read the update which can be sourced at www.asx.com.au | 14/12/2006 |
directors attempt to report on what transpired at the AGM on November 30 is abysmal - one shareholder asked questions about the takeover and at the very least directors should have reported to all shareholders on the substance of the questions and answers | 01/12/2006 |
directors advise of a deteriorating cash position and of attempts to seek further funding | 30/11/2006 |
the meeting to be held at 4:30pm on 30 November at McCullough Robertson, Level 11, Central Plaza Two, 66 Eagle Street, Brisbane is to proceed but it will no longer be an AGM as the company has not finalised the financial statements - it will be a special meeting allowing shareholders to put questions to the board | 24/11/2006 |
company files its quarterly report | 14/11/2006 |
advises in relation to the Chopin Opus bid, that the defeating conditions of the Bidder's Statement (s 3.7) have been waived | 10/11/2006 |
AGM to be held at 4:30pm on 30 November at McCullough Robertson, Level 11, Central Plaza Two, 66 Eagle Street, Brisbane | 08/11/2006 |
ASIC has refused the company's application for an extension of time to hold its AGM and the company will now make arrangements to hold it as soon as practicable | 03/11/2006 |
company secures a $200,000 loan facility for its immediate short term financing needs | 31/10/2006 |
cash flow report for the quarter to 30 September 2006 reflects a deficit at operating level of $1851k for the quarter | 30/10/2006 |
ASX queries the company regarding Listing Rule 10.1 and the company states that it applies to the loan agreement between Anvantogen Oncology and Chopin Opus (see note immediately below) and accordingly the company will seek shareholder approval "for grant of the security by way of promissory note and the issue of the warrants prior to the warrants being issued" | 27/10/2006 |
the company releases a copy of a Form 8-K that has been filed by Avantogen Oncology Inc with the SEC in the US - Avantogen Limited has a 54% interest in Avantogen Oncology Inc - in their release to the ASX, the directors should have explained the implications of this filing for shareholders | 19/10/2006 |
advises of minor amendments to the bidder's statement | 17/10/2006 |
company reports it has sufficient cash to fund activities through to the end of November and is currently seeking additional funding of $200,000 | 17/10/2006 |
releases Bidder's Statement & Target's Statement re the Chopin Opus offer | 05/10/2006 |
Avantogen Ocology Inc submits an investigational drug application to the FDA for a compound being investigated for treatment of pancreatic cancer | 02/10/2006 |
company says it is doing everything possible to resolve the accounting issues underlying its suspension | 27/09/2006 |
Dr William Ardrey appointed CEO and Company Secretary | 25/09/2006 |
advises it has secured a $1.8 million Loan facility | 19/09/2006 |
lodges bidders statement from Chopin Opus | 19/09/2006 |
lodges initial response to bidders statement from Chopin Opus | 19/09/2006 |
releases Preliminary Final Report | 14/09/2006 |
shares suspended from quotation pending resolution of accounting issues | 11/09/2006 |
name changed from Australian Cancer Technology Limited | 31/05/2005 |
Your browser may reflect a date of printing in American format.
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Patrick Elliott | Chairman | |
| William Ardrey | CEO | 29/08/2006 |
| Lauro Valdovinos | Non Exec Director | |
| Yvonne Foong | Director | 13/12/2006 |
| David Sanders | Director | |
| Phillip MacLeod | Company Secretary |
Date of first appointment, title may have changed.
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
